RESUMEN
Objective: Recurrent oral ulcer (ROU) is a common oral mucosal disease with recurrent ulcerative lesions. Shuanghuanglian Oral liquid is a traditional Chinese medicine preparation widely used to treat oral ulcers. This study aimed to explore the effect of Shuanghuanglian oral liquid on the epidermal growth factor (EGF) level in saliva and serum inflammatory factors in patients with recurrent oral ulcers to provide a certain reference for clinical treatment. Methods: A retrospective analysis of 90 ROU patients from 2018 to 2021 was divided into an observation group (n=45) and a control group (n=45). All patients were recruited from Kunming Stomatological Hospital North Downtown Campus. The control group used a mouthwash containing chlorhexidine, while the observation group used the same mouthwash with an additional topical application of Shuanghuanglian. The EGF level in saliva, serum inflammatory factor, clinical efficacy, pain and quality of life scores, recurrence rate, and incidence of adverse reactions were observed in the two groups. Results: After treatment, EGF (RR 0.41, 95%CI 0.15-0.73, P < .001), tumor necrosis factor-α (TNF-α) (RR 0.68, 95%CI 0.53-0.77, P = .003), interleukin-10 (IL-10) (RR 0.64, 95%CI 0.48-0.75, P < .001), and C-reactive protein (CRP) (RR 0.52, 95%CI 0.35-0.65, P < .001) in observation group were significantly lower than those in the control group; The total effective rate of the observation group was significantly higher than that of the control group (RR 0.85, 95%CI 0.44-0.95, P = .02); Visual analogue scale (VAS) (RR 0.48, 95%CI 0.35-0.68, P < .001) and Oral Health Rating Scale (OHIP-4) scores (RR 0.61, 95%CI 0.47-0.84, P < .001)of observation group were significantly lower than those of control group after treatment; The incidence of total adverse reactions (RR 0.73, 95%CI 0.61-0.86, P = .011) and the recurrence rate at 6 months after treatment in the observation group were significantly lower than those in the control group (RR 0.78, 95%CI 0.69-0.91, P = .015). Conclusion: Shuanghuanglian oral liquid has a remarkable effect on patients with ROU by reducing the levels of EGF and inflammatory factors in patients, reducing the pain degree of patients, improving the oral health of patients, improving the quality of life of patients, and reducing the incidence of adverse reactions and the recurrence rate of patients to a certain extent.